Option Care Health reached a fresh annual peak after Morgan Stanley lifted its price target from $35.00 to $38.00 while maintaining an overweight rating. On the same session, trading volume surged to approximately 2.55 million shares, surpassing the 30-day average by more than 20%. Deutsche Bank also raised its objective from $31.00 to $36.00 with a buy rating, and Wall Street Zen shifted its recommendation from hold to buy. Across 14 covering analysts, one assigns a Strong Buy, ten a Buy and three a Hold, yielding a consensus Moderate Buy rating and an average target of $37.17.

Director Harry M. Jansen Kraemer, Jr. added 38,000 shares to his holdings at an average cost of $25.98 per share for a total outlay near $987,240. His direct ownership now stands at 413,390 shares—an increase of 10.12%—with an estimated value of $10.74 million. Insider ownership represents roughly 0.64% of the company’s outstanding shares, underscoring management’s confidence in the infusion services provider’s long-term prospects.

Management raised FY2025 EPS guidance to a range of $1.72–$1.76 per share, above the consensus projection of $1.64, and reiterated stronger-than-expected Q4 profitability. Preliminary Q4 net revenues are estimated between $1.46 billion and $1.47 billion, up from $1.35 billion in the year-ago period. The board also doubled the share repurchase authorization to $1.0 billion, with approximately $193 million remaining under the prior program. FY2026 revenue guidance of $5.8–$6.0 billion trails consensus near $6.1 billion, representing the primary risk to longer-term growth expectations.